RU2018105494A - Улучшенные системы доставки наночастиц - Google Patents
Улучшенные системы доставки наночастиц Download PDFInfo
- Publication number
- RU2018105494A RU2018105494A RU2018105494A RU2018105494A RU2018105494A RU 2018105494 A RU2018105494 A RU 2018105494A RU 2018105494 A RU2018105494 A RU 2018105494A RU 2018105494 A RU2018105494 A RU 2018105494A RU 2018105494 A RU2018105494 A RU 2018105494A
- Authority
- RU
- Russia
- Prior art keywords
- composition according
- therapeutic agent
- nanoparticles
- composition
- prodrug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (17)
1. Фармацевтический состав, включающий набор фармацевтических составов, содержащих наночастицы, где указанные наночастицы имеют средний диаметр менее 80 нм, и содержат:
а) по меньшей мере два терапевтических агента, каждый терапевтический агент соединен через линкер с гидрофобной частью для формирования пролекарства, и
b) амфифильный стабилизатор, содержащий гидрофобную часть и гидрофильную часть, в котором массовое соотношение гидрофобной части к гидрофильной части находится в диапазоне 8:5-12:5 и в котором гидрофобная часть имеет молекулярную массу 8 кДа - 15 кДа.
2. Состав по п. 1, в котором указанный амфифильный стабилизатор представляет собой диблок-сополимер.
3. Состав по п. 1, в котором в указанном амфифильном стабилизаторе гидрофобная часть содержит полимолочную кислоту (PLA) или сополимер молочной и гликолевой кислот (PLGA), и гидрофильная часть содержит полиэтиленгликоль (PEG).
4. Состав по п. 1, в котором по меньшей мере два терапевтических агента включены в одну и ту же наночастицу.
5. Состав по п. 1, в котором один терапевтический агент представляет собой таксан, и другой терапевтический агент представляет собой HSP ингибитор, или где один терапевтический агент представляет собой PI3K/AKT/mTOR ингибитор, и другой терапевтический агент представляет собой RAS/RAF/MEK/ERK ингибитор.
6. Состав по п. 1, в котором в каждом из указанных пролекарств, гидрофобная часть представляет собой холестерин и/или линкер представляет собой дигликолевую кислоту.
7. Состав по п. 1, в котором указанные наночастицы формируются путем смешивания водной фазы и органической фазы, указанная органическая фаза содержит указанный сополимер и указанное пролекарство.
8. Состав по п. 7, в котором указанное смешивание проводится путем быстрого смешивания струйных потоков, один из которых содержит водную фазу и другой содержит органическую фазу.
9. Состав по п. 1, в котором указнные наночастицы имеют средний диаметр 20-80 нм.
10. Состав по п. 1, который дополнительно содержит третий терапевтический агент.
11. Состав по п. 10, в котором указанный третий терапевтический агент поставляется как пролекарство и инкапсулирован в указанные наночастицы.
12. Способ введения комбинации двух или больше терапевтических агентов, способ, который содержит введение к субьекту состава по п. 1.
13. Способ по п. 12, в котором указанное введение осуществляется путем парентерального введения.
14. Способ по п. 13, в котором субъект является человеком или не принадлежащим к человеческому роду млекопитающим или птицей.
15. Способ получения состава по п. 1, способ, который содержит быстрое смешивание водной фазы с органической фазой, содержащей указанный сополимер и указанное пролекарство.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192973P | 2015-07-15 | 2015-07-15 | |
| US62/192,973 | 2015-07-15 | ||
| US201562252396P | 2015-11-06 | 2015-11-06 | |
| US62/252,396 | 2015-11-06 | ||
| PCT/US2016/042330 WO2017011685A1 (en) | 2015-07-15 | 2016-07-14 | Improved nanoparticle delivery systems |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018105494A true RU2018105494A (ru) | 2019-08-15 |
| RU2018105494A3 RU2018105494A3 (ru) | 2019-12-17 |
Family
ID=57757767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018105494A RU2018105494A (ru) | 2015-07-15 | 2016-07-14 | Улучшенные системы доставки наночастиц |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10285951B2 (ru) |
| EP (1) | EP3322404A4 (ru) |
| JP (2) | JP2018521068A (ru) |
| KR (1) | KR20180029242A (ru) |
| CN (1) | CN107920985B (ru) |
| AU (2) | AU2016294617B2 (ru) |
| BR (1) | BR112018000217A2 (ru) |
| CA (1) | CA2991062C (ru) |
| CO (1) | CO2018000146A2 (ru) |
| HK (1) | HK1251159A1 (ru) |
| IL (1) | IL256797B (ru) |
| MA (1) | MA42458A (ru) |
| MX (1) | MX2018000611A (ru) |
| RU (1) | RU2018105494A (ru) |
| SG (1) | SG10201912394VA (ru) |
| WO (1) | WO2017011685A1 (ru) |
| ZA (1) | ZA201800130B (ru) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019100044A1 (en) * | 2017-11-20 | 2019-05-23 | Icahn School Of Medicine At Mount Sinai | Inhibiting trained immunity with a therapeutic nanobilogic composition |
| WO2019178443A1 (en) * | 2018-03-16 | 2019-09-19 | University Of Massachusetts | Yeast cell wall particle encapsulation of biodegradable pro-payloads |
| KR102088663B1 (ko) * | 2018-03-20 | 2020-03-13 | 한국세라믹기술원 | 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도 |
| WO2020123481A1 (en) * | 2018-12-10 | 2020-06-18 | Celator Pharmaceuticals Inc. | Combination formulations of taxanes and mtor inhibitors |
| MX2022001083A (es) * | 2019-08-13 | 2022-05-18 | Peptinovo Biopharma Inc | Micelas lipídicas anfifílicas peptídicas (palm) para tratamiento de neuropatía periférica inducida por quimioterapia relacionada con el tratamiento del cáncer. |
| CN117355298A (zh) | 2021-03-19 | 2024-01-05 | 生物治疗探索股份有限公司 | 用于调节训练免疫的化合物及其使用方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1432402E (pt) * | 2001-10-03 | 2007-02-28 | Celator Pharmaceuticals Inc | Composições para administração de combinações de fármacos |
| US20030118528A1 (en) | 2001-11-19 | 2003-06-26 | Walters Kenneth A. | Topical delivery of codrugs |
| AU2003223226A1 (en) * | 2003-02-20 | 2004-09-17 | University Of Connecticut Health Center | Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
| AU2005269800B8 (en) | 2004-07-19 | 2011-12-01 | Celator Pharmaceuticals, Inc. | Particulate constructs for release of active agents |
| EP1871343A2 (en) * | 2005-04-12 | 2008-01-02 | Wisconsin Alumni Research Foundation | Micelle composition of polymer and passenger drug |
| JP5537753B2 (ja) * | 2007-11-28 | 2014-07-02 | セレーター ファーマスーティカルズ、インク． | 改良されたタキサン送達システム |
| JP2012522055A (ja) * | 2009-03-30 | 2012-09-20 | セルリアン・ファーマ・インコーポレイテッド | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
| JP2013510585A (ja) * | 2009-11-13 | 2013-03-28 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | 癌の同定、評価、予防および治療のための組成物、キットおよび方法 |
| JP5655147B2 (ja) * | 2010-08-20 | 2015-01-14 | セルリアン・ファーマ・インコーポレイテッド | 治療用ペプチド−ポリマーの複合体、粒子、組成物および関連の方法 |
| CN103402517A (zh) | 2010-11-19 | 2013-11-20 | 葛兰素史密斯克莱知识产权（第2号）有限公司 | 使用braf抑制剂的治疗方法 |
| ES2806268T3 (es) * | 2011-04-29 | 2021-02-17 | Selecta Biosciences Inc | Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos |
| US20140308363A1 (en) * | 2011-05-31 | 2014-10-16 | Bind Therapeutics, Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| DE102011109374A1 (de) * | 2011-08-04 | 2013-02-07 | Bock 1 Gmbh & Co. Kg | Stuhl mit Wippmechanik |
| KR20190143491A (ko) * | 2014-06-30 | 2019-12-30 | 타베다 세라퓨틱스, 인코포레이티드 | 표적화된 콘주게이트 및 입자 및 그것의 제형 |
-
2016
- 2016-07-14 EP EP16825199.9A patent/EP3322404A4/en not_active Withdrawn
- 2016-07-14 MX MX2018000611A patent/MX2018000611A/es unknown
- 2016-07-14 MA MA042458A patent/MA42458A/fr unknown
- 2016-07-14 CN CN201680041368.XA patent/CN107920985B/zh active Active
- 2016-07-14 JP JP2018500438A patent/JP2018521068A/ja not_active Withdrawn
- 2016-07-14 RU RU2018105494A patent/RU2018105494A/ru not_active Application Discontinuation
- 2016-07-14 AU AU2016294617A patent/AU2016294617B2/en active Active
- 2016-07-14 BR BR112018000217A patent/BR112018000217A2/pt not_active Application Discontinuation
- 2016-07-14 CA CA2991062A patent/CA2991062C/en active Active
- 2016-07-14 US US15/744,723 patent/US10285951B2/en active Active
- 2016-07-14 WO PCT/US2016/042330 patent/WO2017011685A1/en active Application Filing
- 2016-07-14 KR KR1020187004307A patent/KR20180029242A/ko not_active Application Discontinuation
- 2016-07-14 SG SG10201912394VA patent/SG10201912394VA/en unknown
-
2018
- 2018-01-08 ZA ZA2018/00130A patent/ZA201800130B/en unknown
- 2018-01-08 IL IL256797A patent/IL256797B/en active IP Right Grant
- 2018-01-09 CO CONC2018/0000146A patent/CO2018000146A2/es unknown
- 2018-08-17 HK HK18110619.0A patent/HK1251159A1/zh unknown
-
2019
- 2019-03-15 US US16/355,594 patent/US20190209484A1/en not_active Abandoned
-
2020
- 2020-09-04 US US17/013,101 patent/US11413253B2/en active Active
-
2021
- 2021-11-08 JP JP2021181961A patent/JP2022033751A/ja active Pending
- 2021-12-16 AU AU2021286353A patent/AU2021286353A1/en not_active Abandoned
-
2022
- 2022-07-15 US US17/812,832 patent/US20240366519A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL256797B (en) | 2021-05-31 |
| EP3322404A1 (en) | 2018-05-23 |
| KR20180029242A (ko) | 2018-03-20 |
| CN107920985B (zh) | 2022-03-01 |
| MX2018000611A (es) | 2018-09-06 |
| US11413253B2 (en) | 2022-08-16 |
| MA42458A (fr) | 2018-05-23 |
| ZA201800130B (en) | 2018-12-19 |
| AU2016294617B2 (en) | 2021-09-16 |
| CA2991062C (en) | 2023-06-20 |
| US20210052508A1 (en) | 2021-02-25 |
| JP2022033751A (ja) | 2022-03-02 |
| RU2018105494A3 (ru) | 2019-12-17 |
| CO2018000146A2 (es) | 2018-04-19 |
| CA2991062A1 (en) | 2017-01-19 |
| CN107920985A (zh) | 2018-04-17 |
| US20180207104A1 (en) | 2018-07-26 |
| US10285951B2 (en) | 2019-05-14 |
| EP3322404A4 (en) | 2019-03-20 |
| AU2016294617A1 (en) | 2018-01-25 |
| IL256797A (en) | 2018-06-28 |
| HK1251159A1 (zh) | 2019-01-25 |
| AU2021286353A1 (en) | 2022-01-20 |
| BR112018000217A2 (pt) | 2018-09-04 |
| WO2017011685A1 (en) | 2017-01-19 |
| US20240366519A1 (en) | 2024-11-07 |
| JP2018521068A (ja) | 2018-08-02 |
| US20190209484A1 (en) | 2019-07-11 |
| SG10201912394VA (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018105494A (ru) | Улучшенные системы доставки наночастиц | |
| Tortorella et al. | Zein as a versatile biopolymer: Different shapes for different biomedical applications | |
| Cortés et al. | Non-ionic surfactants for stabilization of polymeric nanoparticles for biomedical uses | |
| Feng et al. | Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment | |
| ES2846809T3 (es) | Métodos y composiciones relacionadas con el uso de tensioactivos de bajo HLB en la producción de nanovehículos sintéticos que comprenden un rapalogo | |
| JP2018500394A5 (ru) | ||
| TWI795421B (zh) | 用於調節至少一種活性成份之藥物釋放動力學的可生物降解之藥物傳遞之組合物混合物 | |
| HRP20200407T1 (hr) | Terapeutske polimerne nanočestice i postupci dobivanja i korištenja istih | |
| JP2015520197A5 (ru) | ||
| EP4393549A3 (en) | Compositions for the delivery of trna as nanoparticles and methods of use therewith | |
| RU2017123358A (ru) | Составы на основе сунитиниба и способы их применения для лечения глазных заболеваний | |
| RU2013109362A (ru) | Кортикостероиды для лечения суставной боли | |
| Uchegbu et al. | Chitosan amphiphiles provide new drug delivery opportunities | |
| WO2015152693A3 (ko) | 신규 이중 나선 올리고 rna 및 이를 포함하는 섬유증 또는 호흡기 질환의 예방 또는 치료용 약학조성물 | |
| WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
| Rafiei et al. | Pharmacokinetic consequences of PLGA nanoparticles in docetaxel drug delivery | |
| WO2016193810A8 (en) | Formation of cyclosporin a/cyclodextrin nanoparticles | |
| AR072668A1 (es) | Encapsulacion de agentes biologicamente activos | |
| Albisa et al. | Polymeric nanomaterials as nanomembrane entities for biomolecule and drug delivery | |
| RU2017111079A (ru) | Фармацевтическая композиция с улучшенной стабильностью | |
| Bahmani et al. | Fabrication of poly (ϵ‐caprolactone)/paclitaxel (core)/chitosan/zein/multi‐walled carbon nanotubes/doxorubicin (shell) nanofibers against MCF‐7 breast cancer | |
| Ataide et al. | Co-encapsulation of drugs for topical application—A review | |
| Li et al. | Drug-loaded star-shaped pH-responsive monomolecular copolymer nanocarriers for tumor targeting and cancer therapy | |
| Jasmine et al. | Polymeric nanoparticles-the new face in drug delivery and cancer therapy | |
| Yang et al. | Recent Applications of PLGA in Drug Delivery Systems |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210301 |